Leerink Swann Raises Price Target on Alexion (ALXN), Sees Upside in Guidance
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann is maintaining its Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) and is raising its price target from $80 to $96 following the release of its Q4 results.
The firm highlights the company's pipeline is beginning to come together. Leerink Swann also noted there is some strong upside potential coming from the company FY12 guidance.
An analyst at Leerink Swann comments, "The company appears to have narrowed its near-term efforts for Soliris to three areas -- kidney transplant, myasthenia gravis, and neuromyelitis optica (NMO). We expect NMO Phase II data in 2012, as early as April at the AAN, and we continue to expect positive data. This expanded use for Soliris as well as asfotase alfa from ALXN's mid- to late-stage pipeline, while the company also has three Phase I agents with the coherent theme of novel agents for ultra-rare diseases."
For FY12, the firm reduced its EPS and revenues estimates from $1.07 billion and $1.64 to $783 million and $1.38.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $80.41 yesterday.
The firm highlights the company's pipeline is beginning to come together. Leerink Swann also noted there is some strong upside potential coming from the company FY12 guidance.
An analyst at Leerink Swann comments, "The company appears to have narrowed its near-term efforts for Soliris to three areas -- kidney transplant, myasthenia gravis, and neuromyelitis optica (NMO). We expect NMO Phase II data in 2012, as early as April at the AAN, and we continue to expect positive data. This expanded use for Soliris as well as asfotase alfa from ALXN's mid- to late-stage pipeline, while the company also has three Phase I agents with the coherent theme of novel agents for ultra-rare diseases."
For FY12, the firm reduced its EPS and revenues estimates from $1.07 billion and $1.64 to $783 million and $1.38.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $80.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
